VRTX
Vertex Pharmaceuticals Incorporated
Healthcare · Biotechnology · United States · Stock
Score Breakdown
Scored for Aggressive Growth profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The composite score of 58.2/100 reflects strong contributions from profitability (perfect score) and momentum (17.0/20), anchored by a dramatic bottom-line turnaround from a FY2024 loss to a FY2025 profit of $3,953,200,000.
- The absence of a dividend (scored zero) and no positive macro theme score both weighed on the composite, preventing a higher overall ranking despite the company's strong operational performance.
- The growth score of 15.0/20 reflects the dramatic net income and EPS recovery, tempered by a more moderate top-line expansion of +8.9%.
Why Not Higher
- Vertex pays no dividend, which scored zero on that factor and structurally limits the composite score regardless of how strong the operational metrics are.
- The macro theme assignments to Biotech & Genomics and Diabetes / GLP-1 / Metabolic Health did not produce a positive theme score under the model's current methodology, leaving additional scoring potential unrealized.
Data Confidence
7 / 10
High — most data fields present
Why This Score
Grounded in figures from this company's SEC EDGAR filings — not a restatement of the score itself.
Revenue grew from FY2024's $11,020,100,000 to FY2025's $12,001,300,000, a gain of +8.9%. Net income swung from a FY2024 loss of -$535,600,000 to a FY2025 profit of $3,953,200,000 (+838.1%), with diluted EPS moving from -$2.08 in FY2024 to $15.32 in FY2025 (+836.5%).
The model rewarded the dramatic bottom-line turnaround — a near-ninefold swing in net income and EPS — while the more moderate top-line expansion of +8.9% likely kept the score from reaching the maximum.
In FY2025, Vertex posted an operating margin of 34.8%, a net margin of 32.9%, and a return on assets of 15.4%, reflecting broad-based profitability across the income statement and balance sheet.
The model awarded a perfect score, recognizing that all three profitability metrics — operating margin, net margin, and return on assets — reached levels consistent with a highly efficient, large-cap biopharmaceutical business in FY2025.
Filing evidence currently available does not support a more specific explanation for this factor.
Revenue across the last four quarters rose from $2,964,700,000 in 2025Q2 to $3,076,400,000 in 2025Q3 and $3,190,000,000 in 2025Q4 before easing to $2,986,900,000 in 2026Q1. Net income followed a similar arc — $1,032,900,000, $1,082,900,000, $1,191,100,000, then $1,031,400,000 — as did operating income, which peaked at $1,205,900,000 in 2025Q4 before pulling back to $1,138,100,000 in 2026Q1.
The model recognized a consistent build through 2025Q4 across revenue, net income, and operating income, with a modest sequential pullback in 2026Q1 that tempered but did not eliminate the positive momentum signal.
Vertex Pharmaceuticals does not currently pay a dividend; this reflects a genuine characteristic of the company, not a data gap.
The model assigns a score of zero for this factor because no dividend income is available to investors, which is a structural feature of how Vertex currently allocates capital.
Vertex Pharmaceuticals is assigned to the macro themes Biotech & Genomics and Diabetes / GLP-1 / Metabolic Health.
Although the company carries two active macro theme assignments, this did not translate into a positive score under the model's current methodology for this factor.
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Vertex Pharmaceuticals delivered strong FY2025 results, with revenue rising to $12,001,300,000 (+8.9% year-over-year) and net income swinging dramatically from a loss of -$535,600,000 in FY2024 to a profit of $3,953,200,000 in FY2025, driving diluted EPS from -$2.08 to $15.32. Profitability metrics were exceptional, with an operating margin of 34.8%, a net margin of 32.9%, and a return on assets of 15.4%, earning a perfect profitability score. Quarterly momentum was broadly positive through 2025Q4 before a modest pullback in 2026Q1, while the absence of a dividend and no positive macro theme score weighed on the composite, resulting in a total model score of 58.2/100 and a Medium risk rating.
Plain English
Vertex had a great year — revenue grew and profits surged from a loss to nearly $4 billion — but it pays no dividend and its sector theme assignments didn't add points, so the overall score lands in the middle at 58.2 out of 100.
Bull Case vs. Bear Case
Bull Case
- Vertex achieved a near-ninefold swing in net income, moving from a FY2024 loss of -$535,600,000 to a FY2025 profit of $3,953,200,000, with diluted EPS rising from -$2.08 to $15.32.
- The company earned a perfect profitability score, posting an operating margin of 34.8%, a net margin of 32.9%, and a return on assets of 15.4% in FY2025 — metrics consistent with a highly efficient large-cap biopharmaceutical business.
- Quarterly revenue built consistently from $2,964,700,000 in 2025Q2 through $3,190,000,000 in 2025Q4, reflecting sustained operational momentum across the core business.
Bear Case
- Vertex does not pay a dividend, meaning investors receive no income return while holding the stock — a structural capital allocation choice that scored zero on the dividend factor.
- Despite being assigned to two macro themes — Biotech & Genomics and Diabetes / GLP-1 / Metabolic Health — neither translated into a positive theme score under the model's current methodology.
- Revenue and operating income both pulled back sequentially in 2026Q1 (revenue to $2,986,900,000 and operating income to $1,138,100,000 from a 2025Q4 peak), introducing a note of caution about near-term trajectory.
What Could Change the Picture
Bullish Triggers
- A resumption of sequential revenue and earnings growth beyond 2025Q4 peaks — particularly if 2026Q1's pullback proves temporary — would reinforce the momentum signal and could lift the composite score.
- If Vertex were to initiate a dividend or meaningful capital return program, it would address the structural zero on the dividend factor that currently weighs on the overall rating.
Bearish Triggers
- If the 2026Q1 sequential decline in revenue and net income deepens in subsequent quarters, the strong momentum signal that contributed to the 17.0/20 momentum score could erode materially.
- Any deterioration in the exceptional FY2025 profitability metrics — operating margin of 34.8% or net margin of 32.9% — would undermine the primary pillar supporting the current composite score.
Risk Profile
Medium RiskThe Medium risk rating reflects a business with strong profitability and broadly positive quarterly momentum through 2025Q4, but the sequential pullback in revenue, net income, and operating income in 2026Q1 introduces uncertainty about whether peak performance levels are sustainable. Financial health details from the filing are limited in the available evidence, adding a degree of opacity to the balance sheet assessment.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.